

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**BIOMED**  
**和 鉑 醫 藥 控 股 有 限 公 司**  
**HBM Holdings Limited**

*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 02142)**

**VOLUNTARY ANNOUNCEMENT**  
**A+++ ROUND FINANCING FOR NK CELL-TECH**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (“**Shareholders**”) and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Shanghai NK Cell Technology Co., LTD (上海恩凱細胞技術有限公司) (“**NK Cell-Tech**”), an investee company of the Company, has recently completed its A+++ round financing, raising a fund of nearly RMB100 million from a group of investors. The proceeds will be used to advance the clinical trials of its core NK cell therapy product candidates and to support the development of its product pipeline.

This successful financing reflects continued progress in NK Cell-Tech’s NK cell therapy development, demonstrating strong investor confidence in its innovative immunotherapy platform, and providing significant funding support to accelerate its clinical and translational advancement.

**About NK Cell-Tech**

NK Cell-Tech is a biotech company focusing on the discovery and development of innovative technology of NK cell therapy. In 2024, one of its NK cell product candidates has obtained investigational new drug (IND) approvals from the Food and Drug Administration (FDA) and the other one has obtained investigational new drug (IND) approvals from the National Medical Products Administration of the PRC (NMPA).

The Company, via Harbour BioMed (Shanghai) Technology Development Co., Ltd (“**HBM Shanghai**”), a subsidiary of the Company, as the co-founder, made an investment in NK Cell-Tech in June 2021. As of 31 December 2024, the Company, through HBM Shanghai, held 10.90% of the total equity interest of NK Cell-Tech.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 9 July 2025

*As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.*